17,261 trials
Recurrent Mantle Cell Lymphoma · Recurrent Non-Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) — 31.8; 0; 7.7 percentage of participants
Respiratory Syncytial Virus
Primary: Time-Weighted Average Change in Nasal Respiratory Syncytial Virus (RSV ) Viral Load From Baseline (Day 1) to Day 9 — -1.26; -0.91 log10 copies/mL — p=0.040
Sickle Cell Disease · Thalassemia · Diamond-Blackfan Anemia
Primary: Count of Participants With Stable Engraftment Post Hematopoietic Cell Transplantation (HCT) — 3 Participants
Infertility
Primary: Number of Oocytes Retrieved — 5.2; 7.9; 9.2; 10.5 Oocytes — p=<0.001
Stroke
Primary: Percent Change in Language Quotient as Assessed by the Western Aphasia Battery — 11.02; -4.2 percent change in language quotient — p=0.008
fMRI · Alcohol Drinking · Alcoholism
Primary: Alcohol Infusions Self-administered — 10.45; 8.80 Number of alcohol infusions
Anti-biotic Resistance
Primary: Oral L. Rhamnosus HN001 Therapy Compared to Placebo on Gastrointestinal and Extra-gastrointestinal Colonization of S. Aureus. — 9; 17; 25; 24 Participants
Metastatic Pancreatic Ductal Adenocarcinoma
Primary: Objective Response Rate (ORR) in All Patients Using Investigator Assessments According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) — 3.1; 0…
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Day 28 in Intent-To-Treat (ITT) Population — 0.027; 0.035 Liters — p=0.57
Sjogren's Syndrome
Primary: Percentage of Participants With a Clinically Relevant Decrease in European League Against Rheumatism (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI) Score…
Coronary Artery Disease · Pain, Postoperative
Primary: Median Cumulative Morphine Equivalent — 0; 2.5; 0; 5 Morphine Equivalents
Respiratory Disorders
Primary: Number of Subjects With Any Solicited Local Adverse Events (AEs). — 49; 5; 9; 0 Participants
Hodgkin's Disease
Primary: Non-myeloablative Maximum Tolerated Dose of I-131 Tositumomab That Can be Given to Patients With Relapsed/Refractory Hodgkin's Lymphoma. — 79 cGy
Osteoporosis
Primary: Percent Change in Lumbar Spine Bone Mineral Density (BMD): Baseline to Week 24 — -0.33; 2.96; 3.47; 4.97 percent change
Mantle Cell Lymphoma
Primary: Progression-free Survival Rate at 18 Months — 88.5; 96 percentage of participants